Sglt 2i CKD Farxiga denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna's Step-Therapy Protocol Blocked Farxiga for CKD — and How to Appeal

Cigna's step-therapy (also called "fail first") protocol for dapagliflozin (Farxiga) in chronic kidney disease requires evidence that you have tried and failed, or are unable to tolerate, one or more preferred or lower-cost medications before Farxiga will be authorized. The denial occurs when that prior-trial history is missing from the authorization request or is not documented in the format Cigna's system requires — even when the trials did occur.

This denial is particularly important to challenge for CKD patients because dapagliflozin has a specific FDA-approved indication for CKD that not all step-therapy alternatives share. If the required prior-step drug is not FDA-approved for CKD — or carries a documented clinical reason it cannot be used for this patient — a bypass exception may apply.

### Why This Denial Is Frequently Overturned

Step-therapy denials succeed on appeal when the prior-treatment history is properly organized and submitted, or when a legitimate bypass provision is identified and documented. Cigna's own coverage policies for SGLT2 inhibitors include bypass criteria — typically covering intolerance, contraindication, or situations where no preferred alternative shares the same FDA-approved indication. Read the current policy carefully and match your clinical facts to the bypass language before filing.

### Federal Appeal Framework

• Internal appeal (ACA / ERISA §503): File within the deadline on the denial letter. Many states also have step-therapy override laws that require plans to grant exceptions when the required prior drug is clinically inappropriate — check your state's rules.
• External review (ACA §2719): If internally denied, file for independent external review within approximately four months. The external reviewer's decision is binding on Cigna.
• Expedited review: If waiting for standard review would seriously jeopardize health, both stages can be expedited — typically 72-hour turnaround.

### Concrete Appeal Steps and Timeline

1. Pull the denial letter and list every step-therapy criterion Cigna identified as unmet. 2. Download Cigna's current clinical policy for SGLT2 inhibitors / dapagliflozin in CKD. Read the step-therapy requirements and bypass provisions in full. 3. For each required prior step, locate the chart records that document the trial: drug name, start and stop dates, the clinical reason for discontinuation or inadequacy. 4. Identify whether a bypass provision applies — intolerance, contraindication, or the required drug lacking the CKD indication — and document it with supporting records. 5. Ask your prescriber and nephrologist (if involved) to write a letter that maps each step-therapy requirement to the chart record and explicitly states which bypass applies if relevant. 6. File the internal appeal with all exhibits. File for external review immediately upon internal denial.

### Documentation to Gather

• Prior-step drug records: Pharmacy fill history, prescriptions, chart notes showing the drug was taken, with dates.
• Failure or intolerance documentation: Chart notes, incident reports, or lab records explaining why each prior step was insufficient or could not be continued.
• FDA labels: For Farxiga and any alternative Cigna requires — compare the CKD indication language directly.
• CKD diagnosis and staging records: Confirming the diagnosis and clinical course.
• Prescriber letter: A detailed, signed letter addressing every step-therapy criterion in order, citing the supporting record for each, and stating the bypass basis if applicable.

### Criteria-Mapping Structure

Use a numbered list or table that mirrors Cigna's step-therapy requirements. For each requirement: state it verbatim, then write the specific chart fact that satisfies it (or the bypass provision that renders it inapplicable), with document name and date. Every requirement must be answered. A reviewer should not have to infer any element of compliance.